21 results about "AdverseEvent" patented technology

An example system includes an implantable medical device configured to obtain measurement values of one or more patient metrics; and processing circuitry configured to: determine a baseline value for each of the respective one or more patient metrics based on measurement values of the one or more patient metrics over a first period of time; determine a short-term value for each of the one or more patient metrics based on measurement values of the one or more patient metrics over a second period of time, determine a difference between each of the short-term values and the respective baseline value for each of the one or more patient metrics; determine that a risk of an adverse event occurring in the patient is high in response to the determined difference meeting a respective adverse event risk threshold; and generate for output an adverse event high risk alert.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

This invention discloses a dynamic prediction system for long-term adverse cardiovascular event risk after stent implantation, belonging to the field of personal health risk assessment technology. It includes: a cardiovascular assessment module for determining the target cardiovascular adverse event presentation coefficient based on the target patient's first chest pain rating and real-time heart rate after stent implantation; a cardiac function assessment module for determining the emphasis of cardiac function analysis at each stage based on the target patient's physical examination data after stent implantation; a probability determination module for determining the probability of the first adverse event based on the target cardiovascular adverse event presentation coefficient and the emphasis of each cardiac function analysis; and an indicator determination module for comparing the target patient's first adverse event probability with the second adverse event probability of each monitored patient to obtain the target cardiovascular risk warning indicator for the target patient. This invention can improve the accuracy of long-term risk prediction for adverse cardiovascular events.

Methods of predicting development of an anticancer therapy-related adverse event (AE) in a subject to be treated with an anticancer therapy, comprising calculating an AE probability score for factors expressed by the subject, and combining the AE probability score to produce a total AE probability score, wherein a total AE probability score is proportional to the subject's probability of developing an AE in response to the anticancer therapy, are provided.

The application provides a kind of prediction method and system of severe adverse events after peroral endoscopic myotomy, comprising the following steps: obtaining the clinical data of patient;The clinical data of the patient is analyzed and screened, so that the influence factor related to severe adverse events after peroral endoscopic myotomy is obtained;The influence factor is analyzed by multivariate logistic regression, so that the independent risk factor related to severe adverse events after peroral endoscopic myotomy is obtained;According to the result of multivariate logistic regression analysis, a risk prediction model is established, and the regression coefficient of integerization is used in the risk prediction model to assign each independent risk factor, so that a risk prediction score system is obtained;The beneficial effects of the application are: the application can intuitively and quantitatively evaluate the risk of severe adverse events after POEM in patients, is easy to apply in clinic, realizes individualized evaluation, and provides a theoretical basis for endoscopists to predict severe adverse events after esophageal POEM.

This invention belongs to the field of biomedical technology, specifically relating to the application of a pharmaceutical composition consisting of denosumab combined with an immune checkpoint inhibitor in the preparation of a drug for treating KRAS-mutant advanced non-small cell lung cancer (NSCLC). Addressing the problems of high toxicity, limited efficacy, and lack of effective prognostic biomarkers in existing maintenance therapy for KRAS-mutant advanced NSCLC, this invention experimentally demonstrates that maintenance therapy with denosumab combined with a PD-1 / PD-L1 inhibitor can significantly prolong overall survival in patients with KRAS-mutant advanced NSCLC who have not progressed after 4-6 cycles of first-line immunochemotherapy, with a lower incidence of treatment-related adverse events and better safety, especially in patients with KRAS-G12C mutations. Furthermore, this invention discovers that plasma CCER2 can serve as a prognostic biomarker. This invention provides a new, low-toxicity, high-benefit strategy for KRAS-mutant advanced NSCLC and also provides a liquid biopsy biomarker that can be used for patient stratification, possessing significant clinical application value.

Disclosed herein are methods of stabilizing or improving lung function in subjects with an interstitial lung disease (ILD) by orally administering a daily amount of between 1600 mg and 2500 mg deupirfenidone. Also disclosed are methods of dose escalation for initial titration, methods of reducing the incidence of emerging adverse events, and methods of directly transitioning patients from other drugs to deupirfenidone without titration.

The present invention relates to improved injectable pharmaceutical compositions comprising one or more therapeutic compounds, or pharmaceutically acceptable salts thereof, that have been developed to significantly reduce both gastrointestinal adverse events (GI AEs) and any accompanying serious adverse events (SAEs) relative to the high rates of GI AEs and SAEs that presently accompany administration of existing pharmaceutical compositions (whether as oral or injectable formulations) of the same therapeutic compounds. Also provided are processes of manufacture and methods of administering the improved injectable pharmaceutical compositions to patients for the treatment of a disease or disorder, such as obesity or overweightedness.

Methods for prevention and reversal of inflammation.

A method is provided for automatically classifying a patient's clinical description using natural language processing by a computer processor. The clinical description relates to the use of a ventricular assist device to treat the patient. The method includes receiving at least one clinical description comprising text. The method then further includes determining the location of a target word within the text. Furthermore, the method includes determining the presence of at least one negative word within an active region comprising a predetermined number of words, including the target word, appearing immediately before and after the target word within the text. The method then includes determining the presence of at least one body part word within the active region. Finally, the method includes determining that if the active region contains a negative word or a body part word, the clinical description will be ignored.

Disclosed herein are methods of stabilizing or improving lung function in subjects with idiopathic pulmonary fibrosis by orally administering a daily amount of between 1600 mg and 2500 mg deupirfenidone. Also disclosed are methods of dose escalation for initial titration, methods of reducing the incidence of emerging adverse events, and methods of directly transitioning patients from other drugs to deupirfenidone without titration.

The invention relates to a method for the diagnosis, prognosis, risk assessment and / or risk stratification of an adverse event in the health of a postsurgical patient, comprising providing at least one sample of a patient, who has undergone, is undergoing or will undergo surgery, wherein the at least one sample has been isolated from the patient presurgically, perioperative or postsurgically, determining a level of at least one biomarker selected from the group consisting of proADM, PCT and pro ET-1 or fragment(s) thereof in said at least one sample, wherein said level of the at least one biomarker or fragment(s) thereof correlates with the likelihood of said adverse event. In some embodiments the method is used for predicting or diagnosing an elevated or decreased likelihood of a postsurgical infection or blood infection. In some embodiments the method is used for predicting or diagnosing an elevated or decreased likelihood of a postsurgical adverse cardiovascular or cerebrovascular event, preferably a major adverse cardiovascular or cerebrovascular event (MACCE), major myocardial injury after non-cardiac surgery (MINS) or perioperative myocardial injury (PMI). In some embodiments the method additionally comprises therapy guidance, stratification and / or control in relation to said postsurgical adverse events, in particular an infection or an adverse cardiovascular or cerebrovascular event.

The disclosure relates to a substance adiponectin and / or adiponectin receptor agonist (ARA) for use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the subject is preferably receiving checkpoint blockade therapy as a cancer therapy. As well as to a combination medication comprising adiponectin and / or adiponectin receptor agonist (ARA) and a photosensitizing agent for combined use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the treatment further comprises the extracorporeal irradiation of a blood sample of the subject with ultraviolet A (UVA), preferably extracorporeal photopheresis (ECP) therapy.

This disclosure relates to a method for treating psoriasis vulgaris, comprising administering the anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to a pharmaceutical composition of the anti-IL-23p19 antibody hum13B8-b or its antigen-binding fragment for the treatment of psoriasis vulgaris in a patient. This disclosure further relates to the use of the anti-IL-23p19 antibody hum13B8-b or its antigen-binding fragment for the manufacture of a pharmaceutical product for the treatment of psoriasis vulgaris in a patient. In some embodiments, the Disclosure relates to methods, pharmaceutical compositions, and pharmaceuticals for treating psoriasis vulgaris, wherein the treatment results in the patient maintaining a physician's global assessment (PGA) score of “clear” or “nearly clear,” with a reduction of at least 2 points from baseline, or the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100), for at least about 60 weeks to at least about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and pharmaceuticals for treating psoriasis vulgaris, wherein the treatment prevents the patient from experiencing an increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least about 60 weeks to at least about 432 weeks.

Provided are methods of treating subjects in need of an anti-fibroblast growth factor receptor 3 (anti-FGFR3) therapy. The methods comprise administering to the subjects a therapeutically effective amount of a peroxisome proliferator-activated receptor (PPAR) alpha agonist in combination with the anti-FGFR3 therapy. The methods can comprise administering to the subject a therapeutically effective amount of PPAR alpha agonist and a bile acid sequestrant. Also provided are compositions comprising an FGFR3 inhibitor, a PPAR alpha agonist, and, optionally, a bile acid sequestrant. The methods attenuate the dysregulation of bile acid biosynthesis caused by FGFR3 inhibition with anti-FGFR3 therapies. The methods reduce the severity and / or incidence of adverse events associated with anti-FGFR3 therapies.

This invention provides a method for constructing a drug adverse reaction risk prediction model, belonging to the field of prediction model construction technology. The method includes: integrating multi-source data on Parkinson's disease to obtain modeling samples; using temporal coding of therapeutic drugs in preprocessing to obtain an initial feature set; and screening and commonality processing of the initial feature set based on potential risk factors to obtain a current feature set; using the SHAP algorithm to obtain key features affecting adverse event prediction, achieving dual interpretability analysis of global key feature identification of the intermediate model and interpretation of driving factors for individual patient prediction results; performing internal and external validation on the interpreted model, and optimizing the model based on the validation results to obtain the final model, ensuring the comprehensiveness of risk assessment.

Methods for prevention and reversal of inflammation.

A predictive biomarker, being a programmed death cell 1 (PD-1) single nucleotide polymorphisms (SNPs), is used in an in vitro method for predicting development of immune-related adverse events (irAEs) in cancer patients, in particular patients undergoing to treatment with immune checkpoint inhibitors (ICIs) and having a higher likelihood of developing said adverse events, is disclosed.

This invention provides a biomarker for poor collateral circulation, UBE2L3, and its applications, belonging to the field of biomedical technology. This invention clarifies for the first time the crucial role of UBE2L3 in inhibiting the formation of collateral circulation in chronic total coronary artery occlusion (CTO), and establishes the "UBE2L3-Parkin-Drpl" axis as a key endogenous inhibitory pathway regulating CTO collateral circulation. This provides a clear and well-defined intervention target for developing novel precision therapies that promote therapeutic angiogenesis, solving the problems of unstable efficacy and off-target risks caused by the broad target scope of current pro-angiogenic strategies. It offers a novel non-surgical biological treatment strategy aimed at enhancing endogenous angiogenesis, potentially fundamentally improving myocardial ischemia and thus reducing the risk of long-term adverse events such as myocardial infarction and heart failure.

This invention relates to a device and medium for assessing the risk of inadequate bowel preparation in patients taking oral magnesium sulfate. The device includes: a data acquisition module for acquiring various risk assessment indicators for patients taking oral magnesium sulfate, including indicators of stroke or dementia, inflammatory bowel disease, heart or kidney failure, colonic stenosis, medication history, dietary type, taste of laxatives, preferred laxatives, history of failed bowel preparation, adverse events, complete administration, and yellow watery stools; and a bowel preparation inadequate risk assessment module for assigning values ​​to the acquired risk assessment indicators to assess the risk of inadequate bowel preparation. Compared with existing technologies, this invention has the advantages of comprehensively and accurately assessing the risk of inadequate bowel preparation, and has good discrimination and calibration.

Machine learned neural networks or machine learning algorithms may be used in a variety of healthcare methods and systems, such as those relating to drug delivery, drug therapies, and / or infusion pumps. The machine-learned neural networks may receive and process data to provide one or more outputs, such as recommended dose limit settings, potential adverse events, medication misuses, occlusion occurrences, extravasations and / or disconnections, pump failures, and maintenance needs. The machine learning algorithms may be trained on a corpus of relevant data to identify recommended dose limit settings, potential adverse events, medication misuses, occlusion occurrences, extravasations and / or disconnections, pump failures, and maintenance needs.